Abound Wealth Management’s GSK GSK Stock Holding History

Abound Wealth Management’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$15.6K	Buy	297 +1	+0.3%	+$53	﹤0.01%	411
2026 Q1	$16.3K	Sell	296 -28	-9%	-$1.52K	﹤0.01%	436
2025 Q4	$15.9K	Buy	324 +238	+277%	+$11.1K	﹤0.01%	409
2025 Q3	$3.71K	Buy	86 +68	+378%	+$2.66K	﹤0.01%	713
2025 Q2	$692	Hold	18	–	–	﹤0.01%	832
2025 Q1	$698	Sell	18 -164	-90%	-$6K	﹤0.01%	787
2024 Q4	$6.16K	Buy	182 +160	+727%	+$5.76K	﹤0.01%	485
2024 Q3	$900	Buy	22 +13	+144%	+$532	﹤0.01%	792
2024 Q2	$347	Sell	9 -29	-76%	-$1.22K	﹤0.01%	925
2024 Q1	$1.63K	Sell	38 -1	-3%	-$41	﹤0.01%	704
2023 Q4	$1.44K	Buy	39 +1	+3%	+$36	﹤0.01%	704
2023 Q3	$1.38K	Hold	38	–	–	﹤0.01%	670
2023 Q2	$1.35K	Buy	+38	New	+$1.36K	﹤0.01%	693

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Abound Wealth Management's GSK Position: Q2 2026 in Review

Abound Wealth Management increased its GSK (GSK) stake by 0.34% in Q2 2026, buying an estimated $53 and bringing the position to 297 shares worth $15.6K. The position accounts for ﹤0.01% of the portfolio, ranked #411.

Abound Wealth Management first reported a position in GSK in Q2 2023 and has held it in 13 quarters since. The position peaked at $16.3K in Q1 2026. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Abound Wealth Management held 297 shares of GSK worth $15.6K as of Q2 2026.
Abound Wealth Management bought 1 GSK share in Q2 2026, an estimated $53.
GSK made up ﹤0.01% of Abound Wealth Management's portfolio in Q2 2026, its #411 holding.
Abound Wealth Management first reported a position in GSK in Q2 2023 and has held it in 13 quarters since.
Abound Wealth Management's GSK position peaked at $16.3K in Q1 2026.
1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Abound Wealth Management's 13F filing for Q2 2026, filed 10 Jul 2026.